Showing results (341-350 of 439) with videos related to
Sort By:
Pageof 44
Blood Advances|June 15, 2025
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphomaNeha Akkad, Lei Feng, Jason R Westin, et al.Haematologica|November 30, 2023
Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapyAndrew P Jallouk, Naishu Kui, Ryan Sun, et al.Blood Advances|February 5, 2025
Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomasDai Chihara, Raphael E Steiner, Ranjit Nair, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2019
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline UpdateNigel S Key, Alok A Khorana, Nicole M Kuderer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2017
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell LymphomaJohn P Leonard, Kathryn S Kolibaba, James A Reeves, et al.Oncology (Williston Park, N.Y.)|December 18, 2016
ACR Appropriateness Criteria® Recurrent Hodgkin LymphomaKaren M Winkfield, Ranjana H Advani, Leslie K Ballas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized TrialsQian Shi, Christopher R Flowers, Wolfgang Hiddemann, et al.International Journal of Radiation Oncology, Biology, Physics|March 28, 2021
Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use CriteriaBradford S Hoppe, Ranjana Advani, Sarah A Milgrom, et al.Blood|March 16, 2025
Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagementHaopeng Yang, Wenchao Zhang, Vida Ravanmehr, et al.Blood Advances|April 26, 2024
Defining primary refractory large B-cell lymphomaAllison M Bock, Raphael Mwangi, Yucai Wang, et al.Pageof 44